AHL
MRSN

Abel Hall LLC’s Mersana Therapeutics MRSN Stock Holding History

Abel Hall LLC’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-546
Closed -$4.7K – 311
2025
Q1 		$4.7K Buy
+546
New +$8.43K ﹤0.01% 200

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Abel Hall LLC's MRSN Position: Q2 2025 in Review

Abel Hall LLC sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 546 shares — an estimated $4.7K sold.

Abel Hall LLC first reported a position in MRSN in Q1 2025 and held it in 1 quarter. The position peaked at $4.7K in Q1 2025. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Abel Hall LLC reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Abel Hall LLC sold 546 Mersana Therapeutics shares in Q2 2025, an estimated $4.7K.
  • Abel Hall LLC first reported a position in Mersana Therapeutics in Q1 2025 and held it in 1 quarter.
  • Abel Hall LLC's Mersana Therapeutics position peaked at $4.7K in Q1 2025.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Abel Hall LLC's 13F filing for Q2 2025, filed 23 Jul 2025.